AF
ABCL icon

Allworth Financial’s AbCellera Biologics ABCL Stock Holding History

Allworth Financial’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.4K Sell
11,643
-3,758
-24% -$18.4K ﹤0.01% 2001
2026
Q1 		$53.8K Buy
15,401
+4,127
+37% +$14.8K ﹤0.01% 2268
2025
Q4 		$38.6K Buy
11,274
+10,096
+857% +$45.1K ﹤0.01% 2371
2025
Q3 		$5.93K Buy
1,178
+207
+21% +$912 ﹤0.01% 3455
2025
Q2 		$3.33K Buy
971
+69
+8% +$172 ﹤0.01% 3478
2025
Q1 		$2.35K Sell
902
-380
-30% -$1.09K ﹤0.01% 3145
2024
Q4 		$4.53K Buy
1,282
+931
+265% +$2.59K ﹤0.01% 2810
2024
Q3 		$913 Buy
+351
New +$973 ﹤0.01% 3251
2023
Q4 		– Sell
-335
Closed -$1.54K – 3448
2023
Q3 		$1.54K Buy
335
+290
+644% +$1.76K ﹤0.01% 2667
2023
Q2 		$291 Buy
+45
New +$307 ﹤0.01% 3026

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Allworth Financial's ABCL Position: Q2 2026 in Review

Allworth Financial reduced its AbCellera Biologics (ABCL) stake by 24% in Q2 2026, selling an estimated $18.4K and leaving 11,643 shares worth $91.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2001.

Allworth Financial first reported a position in ABCL in Q2 2023 and has held it in 10 quarters since. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Allworth Financial held 11,643 shares of AbCellera Biologics worth $91.4K as of Q2 2026.
  • Allworth Financial sold 3,758 AbCellera Biologics shares in Q2 2026, an estimated $18.4K.
  • AbCellera Biologics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #2001 holding.
  • Allworth Financial first reported a position in AbCellera Biologics in Q2 2023 and has held it in 10 quarters since.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.